Lineage Cell Therapeutics, Inc. (LCTX) Form 8-K — May 12, 2026

$LCTXForm 8-KItems 2.02, 9.01Filed May 12, 2026, 4:10 PM ET0001193125-26-219421Original filing

On May 12, 2026, Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026. The company generated total revenues of approximately $1.7 million, a net increase of $0.2 million compared to the same period in 2025, primarily driven by collaboration revenue from a new research agreement with William Demant Invest A/S (WDI). The company's operating expenses increased to $9.3 million for the quarter, up $1.3 million from the same period in 2025.

Key figures

Eps Beat: 0
Revenue: 1725
Total Debt: 34140
Cash Position: 53400

Price after filing

1 day: -3.8%7 days: -9.8%30 days: -7.5%

Close on the filing date to close N calendar days later (from $1.33). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.